08:48 AM EDT, 10/18/2024 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Friday that its Arcutis Canada subsidiary has received regulatory approval from Health Canada for Zoryve topical foam 0.3% to treat seborrheic dermatitis in patients aged 9 and older.

The approval was based on data from a phase 3 study, along with findings from a phase 2 study, a long-term open-label extension study, and a phase 1 pharmacokinetic study, the biopharmaceutical company said.

Price: 9.63, Change: +0.14, Percent Change: +1.48